<DOC>
	<DOCNO>NCT00810797</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use exemestane may fight breast cancer lower amount estrogen body make . PURPOSE : This phase II trial study well exemestane work treat postmenopausal woman stage IV breast cancer .</brief_summary>
	<brief_title>Exemestane Treating Postmenopausal Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Progression-free survival 4 month , measure Response Evaluation Criteria Solid Tumors ( RECIST ) . SECONDARY OBJECTIVES : I . Objective response rate ( complete response [ CR ] partial response [ PR ] ) . II . Clinical benefit ( CR , PR , stable disease &gt; = 6 month ) . III . Assessment toxicity . IV . Assessment compliance medication adherence . V. Assessment quality life . VI . Assessment bone health . TERTIARY OBJECTIVES : I . Serial measurement serum estradiol , estrone , estrone sulfate . II . To investigate treatment resistance ( e.g. , expression amphiregulin , epidermal growth factor receptor [ EGFR ] ) , use molecular immunohistochemical analysis blood tumor sample pre- post- ( available ) treatment tissue . Microarray analyse quantitate expression specific estrogen-responsive gene ( e.g . thyroid transcription factor 1 [ TTF1 ] PDZK1 ) also perform . OUTLINE : Patients receive exemestane orally ( PO ) daily ( QD ) day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Histologically cytologically confirm metastatic carcinoma breast Hormone receptor ( estrogen receptor [ ER ] and/or progesterone receptor [ PR ] ) positive disease ( define : ER and/or PR positivity &gt; = 5 % staining ) , confirm immunohistochemistry ( IHC ) base primary breast tissue metastatic tissue Postmenopausal , define follow : Natural menopause , least 1 year since last menses Chemotherapyinduced menopause least 1 year last menses serum luteinizing hormone ( LH ) /folliclestimulating hormone ( FSH ) estradiol level within postmenopausal range History surgical radiationinduced ovarian ablation For woman = &lt; 56 year old history hysterectomy least one ovary intact , serum LH/FSH estradiol level must within postmenopausal range Postmenopausal woman disease recurrence receive either tamoxifen nonsteroidal aromatase inhibitor ( AI ) adjuvant therapy ( long adjuvant hormonal therapy take 6 month disease progression ) disease recurrence follow discontinuation/completion adjuvant hormonal therapy Postmenopausal woman disease progression follow either 0 , 1 2 prior hormonal therapy metastatic breast cancer , long subject prior exposure exemestane ( EXE ) Measurable nonmeasurable ( evaluable ) disease , define RECIST criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Neutrophil count &gt; = 1.5 X 10^9 cells/L Platelet count &gt; = 100 X 10^9 cells/L Serum creatinine = &lt; 1.5 time upper limit normal ( ULN ) Total serum bilirubin = &lt; 1.5 time ULN Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) level = &lt; 2.5 x ULN patient without liver metastasis = &lt; 5 time ULN patient liver metastasis Alkaline phosphatase = &lt; 2.5 time ULN patient without bone liver metastases Subjects must estimate life expectancy great 6 month Prior exposure EXE , whether adjuvant metastatic set Prior history cancer exception nonmelanoma skin cancer treat situ carcinoma cervix Active symptomatic central nervous system ( CNS ) metastasis ( stable treat brain metastasis allow patient must decadron , give CNS disease ) Hormonereceptor negative unknown breast cancer More two prior chemotherapy regimen treatment metastatic disease ( prior chemotherapy give adjuvant setting permit ) Administration anticancer therapy within 2 week initiate study treatment ; use bisphosphonates , however , permit patient know bone metastasis Treatment concurrent investigational agent antitumor drug ( chemotherapy , antibody therapy biologic agent ) , permit Subjects prior exposure endocrine therapy Any uncontrolled medical comorbidity psychiatric disorder interferes ability provide inform consent comply study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>